Unknown

Dataset Information

First in human study with a prodrug of galantamine: Improved benefit-risk ratio?


ABSTRACT:

Introduction

Gln-1062 (Memogain) is a pharmacologically inactive prodrug of galantamine. Owing to its lipophilic nature, it preferentially enters the brain, where it is cleaved into active galantamine. Gln-1062 is expected to have fewer peripheral side effects than other cholinesterase inhibitors, with improved effectiveness.

Methods

This was a double-blind, comparator and placebo-controlled, sequential cohort, single ascending dose study in 58 healthy subjects with Gln-1062 in doses of 5.5, 11, 22, 33, and 44 mg, compared with oral galantamine 16 mg and donepezil 10 mg. Safety, tolerability, pharmacokinetics, and pharmacodynamics were assessed.

Results

Gln-1062 doses up to 33 mg were well tolerated and induced a dose-dependent increase in the plasma concentrations of

SUBMITTER: Baakman AC 

PROVIDER: S-EPMC5644278 | biostudies-literature | 2016 Jan

REPOSITORIES: biostudies-literature